Our results provided insight into molecular basis on the relationship between PPAT and PCa progression and envisioned the potential use of CTGF as a prognostic biomarker and the TGF-β receptor as potential therapeutic target in patients with metastatic PCa. The gene discussed is CCN2; the disease is posterior cortical atrophy.